RadNet price target raised to $80 from $70 at Truist

Truist analyst David MacDonald raised the firm’s price target on RadNet to $80 from $70 and keeps a Buy rating on the shares. The firm remains bullish on the name following “upbeat” management meetings focused on strong core trends, the company’s attractive positioning in a brisk demand backdrop, and several areas of growth opportunity, the analyst tells investors in a research note. RadNet’s strong core demand should be aided by robust de novo development with over 20 centers slated to open by the end of FY25, Truist notes, adding that it also likes the company’s ongoing opportunity around Digital Health and AI investment.